Cargando…

Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors

BACKGROUND: Antipsychotic medications are not recommended for the management of symptoms of dementia, particularly among persons with no behavioral or psychological symptoms. We examine patterns of antipsychotic medication use among persons with dementia across health sectors in Canada, with a focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios, Sebastian, Perlman, Christopher M., Costa, Andrew, Heckman, George, Hirdes, John P., Mitchell, Lori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651600/
https://www.ncbi.nlm.nih.gov/pubmed/29061129
http://dx.doi.org/10.1186/s12877-017-0636-8
_version_ 1783272925408788480
author Rios, Sebastian
Perlman, Christopher M.
Costa, Andrew
Heckman, George
Hirdes, John P.
Mitchell, Lori
author_facet Rios, Sebastian
Perlman, Christopher M.
Costa, Andrew
Heckman, George
Hirdes, John P.
Mitchell, Lori
author_sort Rios, Sebastian
collection PubMed
description BACKGROUND: Antipsychotic medications are not recommended for the management of symptoms of dementia, particularly among persons with no behavioral or psychological symptoms. We examine patterns of antipsychotic medication use among persons with dementia across health sectors in Canada, with a focus on factors related to use among those without behavioral or psychotic symptoms. METHODS: Using a retrospective cross-sectional design, this study examines antipsychotic use among adults aged 65 or older with dementia in home care (HC), complex continuing care (CCC), long-term care (LTC), and among alternate level care patients in acute hospitals (ALC). Using clinical data from January 1, 2009 to December 31, 2014, the prevalence of antipsychotic medication use was estimated by the presence of behavioral and psychotic symptoms. Logistic regression was used to identify sector specific factors associated with antipsychotic use in the absence of behavioral and psychotic symptoms. RESULTS: The total prevalence of antipsychotic use among older adults with dementia was 26% in HC, 54% in ALC, 41% in CCC, and 48% in LTC. This prevalence ranged from 38% (HC) to 73% (ALC) for those with both behavioral and psychotic symptoms and from 15% (HC) to 31% (ALC) among those with no symptoms. The regression models identified a number of variables were related to antipsychotic use in the absence of behavior or psychotic symptoms, such as bipolar disorder (OR = 6.63 in CCC; OR = 5.52 in LTC), anxious complaints (OR = 1.54 in LTC to 2.01 in CCC), and wandering (OR = 1.83 in ALC). CONCLUSIONS: Potentially inappropriate use of antipsychotic medications is prevalent among older adults with dementia across health sectors. The variations in prevalence observed from community to facility based care suggests that system issues may exist in appropriately managing persons with dementia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12877-017-0636-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5651600
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56516002017-10-26 Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors Rios, Sebastian Perlman, Christopher M. Costa, Andrew Heckman, George Hirdes, John P. Mitchell, Lori BMC Geriatr Research Article BACKGROUND: Antipsychotic medications are not recommended for the management of symptoms of dementia, particularly among persons with no behavioral or psychological symptoms. We examine patterns of antipsychotic medication use among persons with dementia across health sectors in Canada, with a focus on factors related to use among those without behavioral or psychotic symptoms. METHODS: Using a retrospective cross-sectional design, this study examines antipsychotic use among adults aged 65 or older with dementia in home care (HC), complex continuing care (CCC), long-term care (LTC), and among alternate level care patients in acute hospitals (ALC). Using clinical data from January 1, 2009 to December 31, 2014, the prevalence of antipsychotic medication use was estimated by the presence of behavioral and psychotic symptoms. Logistic regression was used to identify sector specific factors associated with antipsychotic use in the absence of behavioral and psychotic symptoms. RESULTS: The total prevalence of antipsychotic use among older adults with dementia was 26% in HC, 54% in ALC, 41% in CCC, and 48% in LTC. This prevalence ranged from 38% (HC) to 73% (ALC) for those with both behavioral and psychotic symptoms and from 15% (HC) to 31% (ALC) among those with no symptoms. The regression models identified a number of variables were related to antipsychotic use in the absence of behavior or psychotic symptoms, such as bipolar disorder (OR = 6.63 in CCC; OR = 5.52 in LTC), anxious complaints (OR = 1.54 in LTC to 2.01 in CCC), and wandering (OR = 1.83 in ALC). CONCLUSIONS: Potentially inappropriate use of antipsychotic medications is prevalent among older adults with dementia across health sectors. The variations in prevalence observed from community to facility based care suggests that system issues may exist in appropriately managing persons with dementia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12877-017-0636-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-23 /pmc/articles/PMC5651600/ /pubmed/29061129 http://dx.doi.org/10.1186/s12877-017-0636-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rios, Sebastian
Perlman, Christopher M.
Costa, Andrew
Heckman, George
Hirdes, John P.
Mitchell, Lori
Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title_full Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title_fullStr Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title_full_unstemmed Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title_short Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors
title_sort antipsychotics and dementia in canada: a retrospective cross-sectional study of four health sectors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651600/
https://www.ncbi.nlm.nih.gov/pubmed/29061129
http://dx.doi.org/10.1186/s12877-017-0636-8
work_keys_str_mv AT riossebastian antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors
AT perlmanchristopherm antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors
AT costaandrew antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors
AT heckmangeorge antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors
AT hirdesjohnp antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors
AT mitchelllori antipsychoticsanddementiaincanadaaretrospectivecrosssectionalstudyoffourhealthsectors